Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.1320 USD
−52.67 M USD
2.43 M USD
19.02 M
About Lucid Diagnostics Inc.
Sector
Industry
CEO
Lishan Aklog
Website
Headquarters
New York
Founded
2018
FIGI
BBG012NYMLC0
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of LUCD is 0.9990 USD — it hasn't changed in the past 24 hours. Watch Lucid Diagnostics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lucid Diagnostics Inc. stocks are traded under the ticker LUCD.
LUCD stock has fallen by −3.01% compared to the previous week, the month change is a 15.45% rise, over the last year Lucid Diagnostics Inc. has showed a −24.32% decrease.
We've gathered analysts' opinions on Lucid Diagnostics Inc. future price: according to them, LUCD price has a max estimate of 7.25 USD and a min estimate of 2.00 USD. Watch LUCD chart and read a more detailed Lucid Diagnostics Inc. stock forecast: see what analysts think of Lucid Diagnostics Inc. and suggest that you do with its stocks.
LUCD reached its all-time high on Oct 14, 2021 with the price of 13.5200 USD, and its all-time low was 0.6301 USD and was reached on Apr 25, 2024. View more price dynamics on LUCD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LUCD stock is 6.25% volatile and has beta coefficient of 0.43. Track Lucid Diagnostics Inc. stock price on the chart and check out the list of the most volatile stocks — is Lucid Diagnostics Inc. there?
Today Lucid Diagnostics Inc. has the market capitalization of 53.94 M, it has increased by 1.24% over the last week.
Yes, you can track Lucid Diagnostics Inc. financials in yearly and quarterly reports right on TradingView.
Lucid Diagnostics Inc. is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
LUCD earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.21 USD resulting in a 2.91% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Lucid Diagnostics Inc. earnings.
Lucid Diagnostics Inc. revenue for the last quarter amounts to 1.17 M USD, despite the estimated figure of 1.14 M USD. In the next quarter, revenue is expected to reach 1.39 M USD.
LUCD net income for the last quarter is −12.37 M USD, while the quarter before that showed −11.01 M USD of net income which accounts for −12.41% change. Track more Lucid Diagnostics Inc. financial stats to get the full picture.
No, LUCD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 70.00 employees. See our rating of the largest employees — is Lucid Diagnostics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lucid Diagnostics Inc. EBITDA is −43.56 M USD, and current EBITDA margin is −1.89 K%. See more stats in Lucid Diagnostics Inc. financial statements.
Like other stocks, LUCD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lucid Diagnostics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lucid Diagnostics Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lucid Diagnostics Inc. stock shows the buy signal. See more of Lucid Diagnostics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.